Heparin-induced thrombocytopenia

Hellenic Journal of Cardiology

Volumn 45, Issue 3, 2004, Pages 178-186

  Betrosian, Alex P ^a   Zamparas, Panagiotis P ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Heparin; Thrombocytopenia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN DERIVATIVE; STREPTOKINASE;

ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; LUNG EMBOLISM; PATHOPHYSIOLOGY; REVIEW; SKIN NECROSIS; THROMBOCYTE COUNT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 27944510492     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Fabris F, Luzzatto G, Stefani PM, Girolami B, Cella G, Girolami A: Heparin-induced thrombocytopenia. Haematologica 2000; 85: 72-81.
2. Davey MG, Lancler H: Effect of injected heparin on platelet levels in man. J Clin Pathol 1968; 21: 55-59.
3. Fabris F, Fussi F, Casonato A, Visentin L, Randi M, Smith MR, et al: Normal and low molecular weight heparins: interaction with human platelets. Eur J Clin Invest 1983; 13: 135-139.
4. Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 78: 1-7.
5. Chong BH: Heparin-induced thrombopenia. Br J Haematol 1995; 89: 431-439.
6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al: Heparin-induced thrombocytopenia treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
7. Warkentin TE, Kelton JG: Heparin and platelets. Hematol Oncol Clin North Am 1990; 4: 243-264.
8. Chong BH: Heparin-induced thrombopenia. Aust NZ J Med 1992; 22: 145-152.
9. Lee DP, Warkentin TE: Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 2nd ed. New York: Marcel Dekker Inc; 2001: 87-121.
10. Warkentin TE, Sheppard JL, Horsewood P, Simpsom PJ, Moore JC, Kelton JG: Impact on the patient population on the risk of heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
11. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, et al: Antibodies to platelet factor-4 after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536.
12. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452.
13. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J: Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review. Arch Pathol Lab Med 2000; 124: 1657-1666.
14. Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the college of American Pathologists. Arch Pathol Lab Med 2002; 126: 1414-1423.
15. Chong BH, Eisbacher M: Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 3-8.
16. Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-555.
17. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 9-18.
18. Warkentin TE: Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost 2001; 85: 947-949.
19. Hach-Wunderle V, Kainer K, Krug B, Mueller-Berghaus G, Potzch B: Heparin-associated thrombosis despite normal platelet counts. Lancet 1994; 344: 469-470.
20. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507.
21. Boshkov L, Warkentin TE, Hayward CPM, Andrew M, Kelton JG: Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-328.
22. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999; 82: 439-447.
23. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S-510S.
24. Warkentin TE. Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med 2000; 6: 343-351.
25. Popov D, Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997; 29: 449-452.
26. Asimacopoulos PJ, Athanasiadis I, McCarthy JJ, Shade RJ, Teague RB: Can heparin cause adult respiratory distress syndrome by a similar mechanism as heparin-associated thrombocytopenia? Chest 1994; 105: 1266-1268.
27. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF: Failure of early heparin cessation as treatment for heparin-induced thrombopenia. Am J Med 1999; 106: 629-635.
28. Kadidal W, Mayo DJ, Horne MK: Heparin-induced thrombopenia (HIT) due to heparin flushes: a report of three cases. J Intern Med 1999; 245: 325-329.
29. Laster JL, Nichols WK, Silver D: Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Circ J 2003; 67: 96-98.
30. Lubenow N, Greinacher A: Hirudin in heparin-induced thrombocytopenia. Semin Thromb Hemost 2002; 28: 431-438.
31. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-2378.
32. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia Circulation 2001; 103: 1838-1843.
33. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57: 177-184.
34. Ibbotson T, Perry CM: Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002; 62: 2283-2314.
35. Dager WE, White RH: Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002; 36: 489-503.
36. Sciulli TM, Mauro VF: Pharmacology and clinical use of bivalirudin. Ann Pharmacother 2002; 36: 1028-1041.
37. Gallus AS, Coglan DW: Heparin pentasaccharide. Curr Opin Hematol 2002; 9: 422-429.
38. Antoniou T, Kapetanakis EI, Theodoraki K, Rellia P, Thanopoulos A, Kotiou M, et al: Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 2002; 5: 354-357.
39. Pinto DS, Sperling RT, Tu TM, Cohen DJ, Carrozza JP Jr: Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Catheter Cardiovasc Interv 2003; 58: 65-68.
40. Warkentin TE: Current agents for the treatment of patients with heparin-induced thrombocytopenia. Curr Opin Pulm Med 2002; 8: 405-412.
41. Manfredi JA, Wall RP, Sane DC, Braden GA: Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Catheter Cardiovasc Interv 2001; 52: 468-472.
42. Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, et al: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000; 12 Suppl F: 14-19.
43. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombopenia. N Engl J Med 2001; 344: 1286-1292.
44. Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A: Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199-1200.
45. Alving BM: How I treat heparin-induced thrombopenia and thrombosis. Blood 2003; 101: 31-37.
46. Warkentin TE, Elavanthil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-812.
47. Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC: Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombopenia. Am J Hematol 2002; 71: 50-52.